Please assess the completion status of the following clinical trial:

Trial Title: XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults \>18yo incarcerated in NYC jails with known release dates.~* DSM-V criteria for current opioid use disorder (DSM-IV opioid dependence).~* Currently maintained on sublingual buprenorphine-naloxone in the NYC jail opioid treatment program.~Exclusion Criteria:~* Individual not interested in XRB treatment. Current SLB patients are otherwise by definition appropriate for XRB.~* Pregnant or planning conception. A urine dipstick pregnancy (hCG) test will be administered at baseline. The test detects human chorionic gonadotropin (hCG) in urine with a sensitivity/specificity of: 25 mIU hCG/ml, \>99%. Time to result is four minutes. If negative, a urine pregnancy test will be administered bi-weekly thereafter to ensure that a participant is not pregnant~* No severe or acute medical or psychiatric disability preventing safe study participation or making follow-up unlikely.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Buprenorphine Extended-Release (Type: EXPERIMENTAL): XRB is a 300mg pre-mixed subcutaneous injectable formulation to be administered monthly. XRB is for abdominal subcutaneous injection only. Participants in the XRB treatment arm will be given 1 or more XRB injections prior to release from jail and one more at week 5 post-release, depending on their release date.
- Sublingual Buprenorphine (Type: ACTIVE_COMPARATOR): SLB (SUBOXONE, Zubsolv, or generic tablets) is a daily sublingual film or tablet ranging from 8-24mg/day or equivalent (Zubsolv is dosed 5.7-17.1 mg/day). The film or tablet is placed under the tongue for 5 to 10 minutes until dissolved completely. Participants in the SLB treatment arm will be provided SLB daily by observed dosing in-jail (controlled substances are not self-administered in-jail) and and encouraged to continue SLB treatment in weekly, bi-weekly, or monthly quantities for unobserved, daily, self-administration through week 5. Patients may also elect to obtain SLB care free-of-charge from the Bellevue Hospital Center Addiction Medicine clinic or from non-NYU/Bellevue providers and pharmacies per usual care standards. SLB will not be provided via the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).